



National Institute for Health and Clinical Excellence

Bevacizumab, sorafenib, sunitinib (second-line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma

Royal College of Nursing

Introduction

With a membership of over 400,000 registered nurses, midwives, health visitors, nursing students, health care assistants and nurse cadets, the Royal College of Nursing (RCN) is the voice of nursing across the UK and the largest professional union of nursing staff in the world. RCN members work in a variety of hospital and community settings in the NHS and the independent sector. The RCN promotes patient and nursing interests on a wide range of issues by working closely with the Government, the UK parliaments and other national and European political institutions, trade unions, professional bodies and voluntary organisations.

Appraisal Consultation Document – RCN Response

The Royal College of Nursing welcomes the opportunity to review the Appraisal Consultation Document (ACD) on the use of bevacizumab, sorafenib, sunitinib (second-line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma.

Nurses working in this area of health have reviewed the ACD and have nothing to add to this appraisal document.

The RCN would welcome guidance to the NHS on the use of these drugs for the treatment of advanced and/or metastatic renal cell carcinoma.

March 2009